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Objectives. To investigate the properties of the strength-duration time constant (SDTC) in multiple sclerosis (MS) patients.
Methods. The SDTC and rheobase in 16MS patients and 19 healthy controls were obtained following stimulation of the right
median nerve at the wrist. Results. SDTC and rheobase values were 408.3 ± 60.0μs and 4.0 ± 1.8mA in MS patients, versus
408.0±62.4μs and 3.8±2.1mA in controls. The diﬀerences were not signiﬁcant in SDTC or rheobase values between the patients
and controls (P = 0.988 for SDTC and P = 0.722 for rheobase). Conclusion. Our study showed no abnormality in relapsing
remitting MS patients in terms of SDTC, which gives some indirect information about peripheral Na+ channel function. This may
indicate that alterations in the Na+ channel pattern in central nervous system (CNS) couldnot be shown in the peripheral nervous
system (PNS) in the MS patients by SDTC. The opinion that MS can be a kind of channelopathy might be proven by performing
other axonal excitability tests or SDTC in progressive forms of MS.
1.Introduction
Ion channels play an essential role in signal transmission and
production of the action potentials by controlling anion and
cation membrane traﬃc. These channels are important for
normal functioning of the excitable tissues of the nervous
system. Molecular genetics had shown that diseases due to
gene encoding mutations in the ion channel subunits of cell
membranes are channelopathies [1]. Ion channel mutations
may aﬀect whole nervous system. An increasing number
of neurological channelopathies in CNS, PNS, and muscles
have been identiﬁed and have helped to learn the molecules
and cellular processes that underlie electrical excitability and
disorders of excitability [2].
Although channelopathies are often inherited, those
associated with autoimmune mechanisms have also been
recently described [1]. Apart from this, channelopathies
resulting from the aberrant transcription of a normal gene
are named transcriptional channelopathies. Peripheral nerve
injury and multiple sclerosis can lead to altered transcription
[3].
It has not been proven that multiple sclerosis (MS) is a
channelopathy. Some researchers have proposed that MS can
aﬀect the PNS in addition to the CNS [4–8].
Axonal excitability tests provide information about the
activity of ion channels, energy-dependent pumps, and ion
exchange processes activated during impulse conduction in
peripheral axons. These tests are applied to the study of the
biophysical properties of human peripheral nerves in vivo
and give important information about axonal ion channel
function and also give limited information about the under-
lyingpathophysiologicalmechanismsinvariousneurological
disorders [9, 10]. These measurements are based on the
membrane potentials and other biophysical characteristics
of the axons. The strength-duration time constant (SDTC)
is used in nerve excitability studies and is interpreted as a
measure of axonal excitability that is dependent upon the
biophysical properties of the axonal membrane at the node
of Ranvier. It also provides information about Na+ channel
functioning [10, 11].
Speciﬁc sodium channel isoforms play an important role
in the pathophysiology of MS. They take part in the2 Multiple Sclerosis International
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Figure 1: (a) The relationship between stimulus strength (mA) and stimulus duration (ms) in patient 11. (b) The relationship between
stimulus duration and the stimulus charge in the same patient. The SDTC is given by the intercept of the linear regression line on the
duration axis and was calculated as follows: when y is accepted as zero, x is obtained by dividing 4.1414 by 1.6941, as an example.
restoration of impulse conduction after demyelination,
axonal degeneration, and the mistuning of Purkinje neurons
that leads to cerebellar dysfunction [12, 13].
Although CNS-expressed sodium channels also occur in
peripheral nerves, several additional channels occur mainly
in dorsal root ganglion cells. SCN9A gene encodes the α
subunit of Nav1.7, which occurs in a subset of dorsal root
ganglionneurons,aswellasinsympatheticganglia.Missense
mutationscauseprimaryerythermalgia,paroxysmalextreme
pain disorder, and insensitivity to pain [14].
In a recent study, it was found that the expression of
acid-sensing ion channel 1 had been associated with axonal
damage in animals. Authors suggested that blockade of
acid-sensing ion channel 1 had the potential to provide
neuroprotective beneﬁts in MS [15]. In another study eval-
uating the sodium channel expression in human astrocytes,
it was suggested that the upregulated expression of Nav1.5 in
astrocytes may support sodium/potassium pump-dependent
ionic homoeostasis in areas of central nervous system injury
[16]. Another study revealed that remyelination of dorsal
column axons by endogenous Schwann cells restored the
normal pattern of sodium and potassium channels at nodes
of Ranvier. These channels might be possible therapeutic
t a r g e t si nf u t u r e[ 17].
Although MS is a disease of the CNS, recently peripheral
nerveinvolvementhasalsobeenproposed.Thepresentstudy
aimed to investigate the properties of the SDTC in MS
patients.
2.MaterialsandMethods
2.1.Participants. Thestudyincluded20patients(13females,
7 males) with relapsing-remitting MS, and 20 gender- and
age-matched healthy controls (13 females, 7 males). The
patients were deﬁnitively diagnosed with MS according
to the criteria of Poser and McDonald [18, 19]. Clinical
severity was evaluated using the Expanded Disability Status
Scale (EDSS) [20]. Patients with comorbid autoimmune
or neoplastic pathologies, peripheral nerve disease, and
systemic/metabolic disease were excluded from the study. In
all, 4 MS patients and 1 control were unable to complete the
study because of intolerance to electrophysiological testing.
Assuch,thestudywasconductedwith16MSpatientsand19
volunteers. All patients gave their personal informed consent
for the study. The study was approved by the Local Ethics
Committee.
2.2. EMG Studies and Formulation. All the electrophysiolog-
ical tests were performed with a 4-channel electromyography
(EMG) machine (Dantec Keypoint, Dantec Dynamics, Bris-
tol, United Kingdom). The SDTC, which is partially depen-
dent upon persistent sodium conductance activity at the
resting membrane potential, was measured from the median
motor axon. Systemic/neurological examination and upper
and lower extremity motor and sensory nerve conduction
studies were performed prior to SDTC measurement.
Right median nerve stimulation was applied at the wrist,
and recordings were made at the abductor pollicis brevis
(APB) muscle in order to obtain compound muscle action
potentials (CMAPs). Skin temperature was monitored close
to the stimulation site and kept at more than 32◦C by placing
a blanket over the palm and using radiant heat if necessary.
The amplitude of the CMAP was measured from baseline
to negative peak, and the target CMAP was set to 40% of
the peak response 1ms in duration. The stimulus strength
that produced the target response for diﬀerent stimulus
durations(0.04,0.1,0.2,0.3,0.5,0.7,and1ms)wasrecorded.
Data were transferred to a computer to obtain stimulus-
response curves showing the relationship between stimulus
strength and stimulus duration (Figure 1(a)). The SDTCs
were calculated using Weiss’s formula [21]. The stimulus
charge was obtained by multiplying the stimulus strength by
stimulus duration. There was a linear relationship between
the stimulus charge and stimulus duration (Figure 1(b)).
Based on the regression equation for this linear relationship,
the SDTC was calculated [22]. The SDTC is the point that is
the intercept of the regression line on the x-axis (durationMultiple Sclerosis International 3
Table 1: Clinical characteristics of MS patients.
Patient Age Number of relapses Disease duration (year) EDSS
13 4 2 3 1
2 30 3 10 1,5
32 5 2 3 1
42 9 3 5 2
52 4 2 4 1
63 7 2 5 1
72 5 2 3 1
83 1 4 1 2 2
92 2 3 3 2
10 39 4 8 2,5
11 37 2 4 1
12 31 3 3 2
13 26 7 8 3,5
14 30 2 4 1
15 40 3 5 1,5
16 43 5 5 3
axis); the rheobase is given by the slope of the regression
line [23]. The evaluator was blind during evaluation of the
patients/controls.
2.3. Statistical Analysis. All data were analyzed using SPSS
v.15.0 statistical software. To compare the SDTC, rheobase,
and CMAP values statistically, the t test was used. Quantita-
tive data are presented as mean ± standard deviation (SD). A
P value < 0.05 was considered statistically signiﬁcant.
3. Results
We examined 16 MS patients (12 females, 4 males) and
19 gender- and age-matched healthy controls (12 females,
7 males). Mean age of the MS patients was 31.44 ± 6.3
years, versus 32.74 ± 7.2 years for the controls. Signiﬁcant
diﬀerences in gender and age were not observed between the
patients and controls (P = 0.580 for age). The mean number
of annual relapses in the MS patients was 3.06 ± 1.38, mean
disease duration was 5.31±2.75 years, and mean EDSS score
was1.68±0.79.ClinicalcharacteristicsoftheMSpatientsare
shown in Table 1.
According to the electrophysiological test results, none
of the participants had polyneuropathy. Mean SDTC and
rheobase values were 408.3 ±60.0μsa n d4 .0 ±1.8mA in the
MS patients and 408.0±62.4μsa n d3 .8±2.1mA in controls,
respectively. There were not any signiﬁcant diﬀerences in
SDTC, rheobase, or CMAP values between the patients and
controls (P = 0.988, P = 0.722, and P = 0.644, resp.).
4. Discussion
Persistent Na+ channels in human motor axons are those
that are active at the resting membrane potential. The SDTC
is dependent upon the membrane potential and is partially
aﬀected by persistent Na+ conductance [24]. Increasing the
fraction of Na+ current that is persistent (or depolarizing
the node) produces a longer SDTC and lower rheobase [10].
It has been shown that the SDTC was longer in patients
with diseases that aﬀect the lower motor neurons/axons
[23, 25]. It has also been suggested that an increase in
persistent Na+ channel expression associated with axonal
regeneration is responsible for this phenomenon. Nerve
regeneration following axonal loss results in increase in the
rate of persistent Na+ channels, persistent Na+ conduction,
and the SDTC.
Multiple sclerosis is a chronic, demyelinating (also
accompanied by axonal destruction) disease of the CNS,
with an unknown etiology. Damage to myelinated ﬁbers
causes defective impulse transmission. Myelinated axons
have more Na+ channels, which play a critical role in impulse
conduction. Some alterations in the Na+ channel pattern
may occur in myelinated ﬁbers aﬀe c t e db yM S[ 13]. In
addition, it has been shown that the number of Na+ channels
increases in the demyelinating lesions of MS. It has also been
proposed that these channels provide Na+ input to neurons,
trigger calcium ions in cells, and ultimately produce the
axonal injury in such neuroinﬂammatory diseases as MS.
It has also been reported that abnormal expression of Na+
channels contributes to the emergence of symptoms of MS
[26–28]. As such, all data regarding the number, subtype,
and distribution of Na+ channels might lead to a greater
understanding of the etiology and pathophysiology of MS.
It has been shown that alterations in the expression pattern
of speciﬁc Na+ channel isoforms are important in remission
and progression of MS. By manipulating these channels, it
might be possible to develop new therapies for MS [13].
Currently, some trials based on the assumption that Na+
channel blockers may be potential neuroprotective agents
in MS are being conducted. A recent study suggested that
loss of Na+ channel β2 subunit is neuroprotective in EAE
by prevention of Na+ channel upregulation in response to
demyelination [29]. As recent studies showed that voltage-
gated Na+ channels are neuroprotective in experimental
models of inﬂammatory demyelinating disease, some Na+
channel blockers have been used for MS. A recent study
that lamotrigine was used for neuroprotection in secondary
progressive multiple sclerosis revealed that sodium-channel
blockade had not prevented cerebral volume loss [30].
Since MS is primarily a disease of the CNS, studies
investigating the relationship between Na+ channels and
MS are limited by the functions of Na+ channels in the
CNS.However,theliteraturecontainsafewstudiesreporting
the PNS involvement in MS. In these studies segmental
demyelination, reduced myelin thickness, hypertrophic neu-
ropathy, prolonged distal latency, decreased amplitude and
conduction velocity, and increased jitter have been observed
[31–36] .T h er o l eo fN a + channels has not been evaluated
since. In the present study, peripheral nerve involvement in
the MS patients was investigated with SDTC. No signiﬁcant
diﬀerence was found between MS patients and the control
group; however, the possible role of peripheral intranodal
Na+ channels in the pathogenesis of MS was evaluated.4 Multiple Sclerosis International
Involvement of the PNS was proposed to be mild and
progressive in MS patients, but no signiﬁcant diﬀerence was
shown at the beginning of the study [7]. Although this study
w a si n v e s t i g a t i n gt h et e m p e r a t u r ee ﬀects on standard nerve
conduction properties but not excitability, the results of the
study regarding progressive peripheral nerve involvement in
MS patients diﬀer from the present study’s results. The fact
that the present study included a small number of patients,
and that disability in MS patients increases over time with
sensory and/or motor deﬁcits in the extremities should be
taken into consideration. A prospective, investigator-blinded
study that evaluated CMAP amplitudes in 4 diﬀerent motor
nerves in 69 MS patients reported signiﬁcant lower mean
CMAP amplitudes in patients than in the controls [37].
The present study examined changes in the SDTC of the
median nerve in relapsing-remitting MS patients to evaluate
impulseconductiondisturbancesintheperipheralaxonsand
investigated the properties of the SDTC in MS patients by
comparing them with those of gender- and age-matched
healthy controls. Signiﬁcant diﬀerences in SDTC, rheobase,
andCMAPvaluesbetweenthestudyandcontrolgroupswere
not observed.
Contrary to Vogt’s ﬁndings, the present study showed no
signiﬁcant diﬀerence between the CMAP amplitudes in the
MS patients and controls (15.0 ± 4.3v e r s u s1 4 .4 ± 3.5, resp.;
P = 0.644). This might have been due to the small number
of patients in the present study and that they had markedly
lower EDSS scores (4.4 ± 0.2v e r s u s1 .68 ± 0.79).
Considering that the SDTC increased due to an increase
in the persistent Na+channel expression associated with
nerve regeneration after axonal injury, the present study is
important because it evaluated the status of Na+ channels
and peripheral nerve involvement in MS patients. It has
been shown that the SDTC was longer in patients with
diseases that aﬀect the lower motor neurons/axons, such
as amyotrophic lateral sclerosis, spinal muscular atrophy,
and peripheral axonal neuropathies [23, 25]. In a recent
s t u d yl o w e rm o t o rn e u r o nl o s si nM Sw a sd e m o n s t r a t e d
electrophysiologically and morphologically [37].
The literature contains a few studies that have evaluated
axonal excitability in MS patients [5, 6, 8, 38, 39]; how-
ever, the SDTC was evaluated in only 1 of these studies
[39]. The other studies assessed other axonal excitability
measurements, such as refractoriness, supernormality, and
threshold tracking [5, 6, 8, 38]. Some studies have shown
that supernormality was reduced in the peripheral nerves of
MS patients [5, 6, 8]. These studies suggest that paranodal
demyelination reduces supernormality due to leakage of the
stored currents [10, 24]. The results of these studies diﬀer
fromthoseofthepresentstudy.Thecauseofthisdiscrepancy
is usage of axonal excitability measurements other than the
STDC.Thepotentialdependenceofsupernormalitydepends
primarily on the paranodal K+ channels, whereas the SDTC
reﬂects the properties of persistent Na+ currents [10].
In another study [38] based on threshold tracking as
an axonal excitability measurement in median motor axons
and superﬁcial radial sensory axons it was reported that
supernormality and threshold electrotonus at the tested sites
(medianmotoraxonsatthewrist,andradialsensoryaxonsat
themid-forearm)weresimilar inthecontrolandMSgroups,
in contrast to the studies that reported that MS patients
have smaller supernormality than normal patients [5, 6, 8].
These results are similar with those of the present study.
Additionally, Misawa et al. reported that approximately 5%
of 60 MS patients developed demyelinating polyneuropathy
[38]. Although the cause of the discrepancy between studies
reporting that supernormality was reduced in the motor
nerves in MS patients and those reporting it was not remains
unclear, it has been suggested that threshold tracking is more
accurate and sensitive for evaluating axonal excitability than
amplitude tracking [24]. Additionally, it has been proposed
that reduced supernormality in previous studies might be
related to secondary changes in paralyzed limbs caused by
MS lesions.
A recent study that included 12 MS patients and 50
healthy controls used the recovery cycle (relative refractory
period, refractoriness at 2ms, supernormality, late subnor-
mality), threshold electrotonus to ±40% currents, and the
current-threshold (I/V) relationship, as well as the SDTC,
to evaluate axonal excitability [39]. The results show that
there were signiﬁcant diﬀerences in supernormality, late sub-
normality, threshold electrotonus to ±40% currents (slow
accommodation to depolarization, depolarizing threshold
at 90–100ms, depolarizing threshold undershoot), and
the current-threshold (I/V) relationship (threshold to 50%
depolarizing current, resting I/V slope, depolarizing I/V
slope) between the 2 groups. MS patients had changes in
physiological measures of axonal excitability attributable to
increased slow K+ channel activity, indicating that these
changesrepresentatranscriptionalchannelopathyduetoup-
regulation of K+ channel expression. This study shows that
SDTC was identical in the 2 groups (P = 0.6331), is the only
study in the literature that assessed the SDTC in MS patients,
and resembles the present study in terms of persistent Na+
channel ﬁndings.
The present study was designed based on the assumption
that Na+ channel variations that have been reported in the
CNS of MS patients might also occur in the PNS. Axonal
membrane excitability was evaluated using the SDTC, which
is an indicator of Na+ channel functioning in peripheral
nerve Ranvier nodes. The data presented suggest that there
were no diﬀerences between the MS patients and healthy
controls in terms of SDTC.
5. Conclusion
Strength duration time constant gives indirect information
about Na+channels. Thus, it might not be correct to consider
that Na+ channels in peripheral nerves of MS are completely
unaﬀected according to our study. The absence of signiﬁcant
diﬀerence in peripheral intranodal Na+ channel functioning
between the MS patients and controls in the present study
indicates that alterations in the Na+ channel pattern, which
have been shown in the CNS of MS patients, could not
be shown in PNS of MS patients by SDTC. As such, we
suggest that CNS pathologies are fundamentally involved in
the pathogenesis of MS, and even if the PNS is aﬀected thisMultiple Sclerosis International 5
might occur mostly during the later stages of the disease.
The opinion that MS is a channelopathy might be proven
by performing other axonal excitability tests or SDTC in
progressive forms of MS. Although persistent Na+ channels
do not appear to play a role in this process, additional
prospective studies (including large number of patients) that
evaluate the properties of the SDTC in MS patients are
needed in order to gather more evidence.
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